Published: January 24, 2019

Introduction {#sec1}
============

Pathological accumulation of phosphorylated Tau (pTau) and accumulation of amyloid-beta (Aβ) fragments are the two major biochemical hallmarks of Alzheimer's disease (AD). Effective strategies to remove Aβ in AD-patient brains have been developed but have not yet shown efficacy to slow cognitive decline in clinical trials. This finding has led to the idea that targeting Tau or combinatorial strategies that target both Tau and Aβ are required to treat AD. While Aβ generation has been studied in much detail, the processes that drive pTau accumulation in AD are poorly defined. Late stage Tau pathology, such as aggregation of accumulated Tau in neurofibrillary tangles (NFT), and subsequent neurodegeneration can be modeled in mice, or non-neuronal human cells, by (over)expression of human mutant Tau. However, Tau mutations do not occur in AD. Instead, in AD, endogenous "wild-type" pTau accumulates downstream of familial AD (FAD) mutations (in APP, PSEN1, and PSEN2 genes) or, in the case of sporadic late-onset AD (SAD), downstream of an unknown combination of genetic and environmental risk factors. How these factors drive early accumulation of pTau in AD is not understood. Recent advances in induced pluripotent stem cell (iPSC) technology ([@bib64]) have made it possible to generate functional human neurons from patients and healthy controls to study early pathophysiological regulation of endogenous Tau. In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points ([@bib12], [@bib29], [@bib47], [@bib50], [@bib53], [@bib63]). Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau ([@bib29], [@bib47]). Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ ([@bib29], [@bib47]).

Identification of other cellular pathways that contribute to pTau accumulation early in FAD and SAD neurons is key to understanding Tau pathology in AD. In addition to increased Aβ and pTau levels, CE also accumulate in FAD and SAD. CE are increased in mouse models expressing human (mutant) APP ([@bib11], [@bib67], [@bib70]) and CE, as well as CE-storage organelles (lipid droplets), have been shown to accumulate in the SAD brain ([@bib11], [@bib19], [@bib23], [@bib70]). CE are generated when cholesterol is converted to CE by the ER-resident Acyl-CoA cholesterol acyltransferase (ACAT) through ligation of a long-chain fatty acid to (excess) cholesterol, and CE can be converted back to cholesterol by acidic lipases in the lysosome ([@bib28], [@bib57]). CE enhance the production of Aβ *in vivo* and *in vitro* indicating that CE can contribute to AD pathogenesis ([@bib15], [@bib25], [@bib26], [@bib56], [@bib57]). CE-dependent regulation of Aβ generation is mediated by altered trafficking of APP through the early secretory pathway ([@bib26]). Whether CE also affect Tau phosphorylation or Tau proteostasis is unknown, but inhibition of cholesterol esterification by genetic deletion of ACAT1 prevents early stage Tau pathology in Tau mutant mice through unknown mechanisms ([@bib65]). A possible way by which CE could affect Tau pathology is through regulation of the ubiquitin-proteasome system (UPS). Cholesterol and cholesterol metabolites extensively interact with the UPS to regulate the ubiquitination and degradation of cholesterol-metabolic enzymes ([@bib60]), and the UPS is a major regulator of pTau proteostasis. ([@bib37]). Activity of the UPS is decreased in AD ([@bib32], [@bib34]), and UPS (re)activation delays Tau aggregation and neurodegeneration *in vitro* and *in vivo* ([@bib24], [@bib40], [@bib51]).

Here, we tested a library of \>1,600 compounds for their potency to inhibit pTau accumulation in cultured FAD iPSC-derived neurons and find that neuronal CE regulate the proteasome-dependent degradation of pTau. Using neurons derived from multiple AD- and non-demented control (NDC) iPSC lines, as well as isogenic CRISPR/Cas9 gene-edited lines, we demonstrate that the effect of CE on pTau is correlated with, but independent of APP processing and Aβ. Whereas the effect of CE on pTau is mediated by proteasomal upregulation, the effect of CE on Aβ secretion is mediated by a cholesterol-binding domain in APP. We identify a number of strategies to reduce pTau in a CE-dependent manner and find that allosteric activation of CYP46A1 is a neuron-specific CE-lowering strategy particularly well tolerated by human astrocytes. Collectively, our data identify a CYP46A1-CE-Tau axis as an early druggable pathway in AD.

Results {#sec2}
=======

A Drug Screen in iPSC-Derived Human FAD Neurons to Identify Compounds that Reduce pTau Accumulation {#sec2.1}
---------------------------------------------------------------------------------------------------

pThr231Tau is an early marker of AD pathology that correlates well with cognitive decline ([@bib9], [@bib41]). pThr231Tau accumulates in APP duplication (APP^dp^) iPSC-derived FAD neurons ([@bib29]). To identify compounds that reduce pTau accumulation in these FAD neurons, we screened a collection of 1,684 approved and preclinical drugs for their efficacy to lower neuronal pThr231Tau. For our screen, neural progenitor cells (NPCs; line APP^dp^1-6) ([@bib29]) were differentiated to neurons ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) for 3 weeks, replated in 384 well plates, and allowed to mature for 2 weeks before treatment with compound at 5 μM for 5 days. The screen was performed in duplicate, and a ratiometric readout of pThr231Tau/total Tau (tTau) level and cell viability was determined ([Figure 1](#fig1){ref-type="fig"}A). In the primary screen, 158/1,684 compounds (9.4%) significantly reduced pThr231/tTau by a *Z* score \<−2 in at least one of the duplicates ([Figure 1](#fig1){ref-type="fig"}B; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}) and were selected for confirmation. In a repeat of the primary assay with selected compounds, 96/158 compounds were confirmed to reduce pThr231/tTau by a *Z* score \<−2 in at least one additional replicate ([Table S3](#mmc3){ref-type="supplementary-material"}). Of the 96 confirmed compounds, 42 were clearly non-toxic hits with *Z* \> −1 for viability ([Figure 1](#fig1){ref-type="fig"}C). Our screen identified six microtubule-interacting compounds that reduced pThr231Tau/tTau (14% of hits) that have previously been shown to regulate pTau in other systems ([@bib16], [@bib44], [@bib69]). Our hit-list also included four inhibitors of cholesterol synthesis; atorvastatin, simvastatin, fluvastatin, and rosuvastatin. Because cholesterol metabolism has been heavily linked to AD pathogenesis ([@bib15]) we selected these compounds for further study. We confirmed that these four statins, as well as two additional statins (lovastatin and mevastatin), reduced pThr231Tau/tTau in a dose-dependent manner with minor effects on cell viability or neuronal number ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C--S1F). Simvastatin reduced pThr231Tau in a similar dose-dependent manner in additional lines from the same patient (APP^dp^1-2) and an independent patient APP^dp^ line (APP^dp^2-1) ([Figure S1](#mmc1){ref-type="supplementary-material"}G), indicating that the effect of statins is conserved across individual APP^dp^ lines and patients. In addition to pThr231Tau/tTau, atorvastatin also reduced pS396/S404Tau, pS202/T205Tau and levels of a pThr231 phosphorylation-dependent conformational Tau epitope (TG3) as assessed by immunofluorescence ([Figure 1](#fig1){ref-type="fig"}e). These data show that in addition to screening for Aβ ([@bib8], [@bib35]), iPSC-derived AD neurons can be applied to screen for pTau modulators. In addition, these data show that statins reduce pTau levels across a number of phosphorylation epitopes and across individual FAD (APP^dp^) patients.Figure 1Identification of Compounds that Decrease pTau Levels in FAD iPSC-Derived AD Neurons(A) Screening strategy overview: APP^dp^1-6 NPC's were differentiated for 3 weeks, replated into 384 well plates, and after 2 weeks, treated with 5 μM of compound for 5 days; pThr231Tau/tTau ratio and cell viability was measured.(B) 1,684 compounds (in pink) were screened in duplicate for their effect on pThr231Tau/tTau ratio as expressed by *Z* score. 158 compounds that decreased pThr231/tTau by *Z* ≤ −2 were selected for confirmation. Vehicle alone controls (DMSO) are shown in black.(C) 42 confirmed non-toxic hits grouped by drug category. SER, selective estrogen reuptake (n = 4).(D) Dosage effects of different statins on pThr231Tau/tTau ratio in APP^dp^1-6 (mean ± SEM, n ≥ 3).(E) APP^dp^1-6 neurons were treated with vehicle (DMSO, upper row) or atorvastatin (10 μM, lower row) for 5 days and fixed and stained with antibodies for indicated antigens. NF-H, neurofilament H, axonal marker. The pThr231Tau antibody used is TG3, which detects a conformational epitope of pThr231Tau. Scale bar, 100 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

The Effect of Statins on pTau Is Mediated by Cholesteryl Esters {#sec2.2}
---------------------------------------------------------------

To understand how pTau is regulated by statins, we studied the relationship between the mevalonate-cholesterol synthetic pathway and pTau levels in more detail. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), an early rate limiting step in the cholesterol synthetic pathway that converts HMG-CoA to mevalonate (MVA) ([Figure 2](#fig2){ref-type="fig"}A). As expected, MVA supplementation rescued the effect of atorvastatin treatment on pThr231Tau/tTau indicating that the effect of statins on pTau is specific to their effects on the mevalonate pathway ([Figure 2](#fig2){ref-type="fig"}B). While atorvastatin was slightly cytotoxic at higher concentrations ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B) toxicity did not explain the effect of atorvastatin on pThr231Tau/tTau, as MVA supplementation completely rescued the effect of atorvastatin on pThr231Tau/tTau ratio without rescuing the minor effect of atorvastatin on cell viability ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Removal of atorvastatin after 5 days of treatment allowed recovery of pThr231Tau/Tau indicating reversible dynamic regulation ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Statin-treated neurons elicited a (normal) physiological response to statin treatment exemplified by upregulation of cholesterol-synthetic proteins ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E; [Table S4](#mmc4){ref-type="supplementary-material"}). Statins have recently been reported to induce the degradation of mutant p53 by reduction of mevalonate-5-phosphate (MVP) ([@bib55]). The effects of statins on pTau are not mediated by MVP, as both MVP and its direct downstream metabolite, MVA-5PP, rescued the effect of statin treatment ([Figure 2](#fig2){ref-type="fig"}B). More distal of MVA-5PP, the MVA pathway branches into non-sterol isoprenoid (protein prenylation) pathways and a cholesterol synthetic pathway ([Figure 2](#fig2){ref-type="fig"}A). Inhibition of the respective non-sterol isoprenoid pathways (by geranyl- or farnesyl-transferase inhibitors GGTI-298 and FTI-227, respectively) did not significantly reduce pThr231Tau/tTau ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G). In contrast, inhibition of the cholesterol-synthetic arm of the mevalonate pathway using a squalene synthase inhibitor (YM-53601) or Δ7-dehydrocholesterol reductase (DHCR7) inhibitor (AY-9944) did significantly decrease pThr231Tau/tTau ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G), indicating that pTau is regulated by the cholesterol-synthetic branch of the MVA pathway. Alternative ways to reduce neuronal cholesterol such as inhibition of sterol regulatory element-binding protein (SREBP)-mediated transcriptional activation of cholesterol synthetic genes by fatostatin ([@bib30]) ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}H, and S2I) or induction of cholesterol export by liver X receptor (LXR) agonists ([Figure 2](#fig2){ref-type="fig"}A) T0901317 and 24-hydroxycholesterol ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G) also reduced pThr231Tau/tTau. Activation of homologous nuclear receptors such as PPARα (by GW50156) and PPARγ (by Rosiglitazone), which regulate fatty acid metabolism but not cholesterol export, did not decrease pThr231Tau/tTau ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G). Another strategy to reduce the pool of neuronal cholesterol is the activation of cholesterol 24-hydroxylase (CYP46A1), a neuron-specific enzyme that converts cholesterol to 24-hydroxycholesterol ([@bib1], [@bib43], [@bib48]). As expected, activation of CYP46A1 by efavirenz ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G) or overexpression of CYP46A1 ([Figures S2](#mmc1){ref-type="supplementary-material"}J and S2K) also reduced pThr231Tau/tTau. Together, these data show that mechanistically different cholesterol-lowering drugs all reduce pTau, strongly indicating that pTau levels are controlled by neuronal cholesterol levels or downstream cholesterol metabolites. To determine whether cholesterol itself or a cholesterol metabolite controls pTau levels, we performed extensive lipid analysis for key selected compounds from previous experiments ([Figures 2](#fig2){ref-type="fig"}D--2F and [S2](#mmc1){ref-type="supplementary-material"}L--S2P; [Table S5](#mmc1){ref-type="supplementary-material"}). None of the pTau-reducing drugs affected phospholipid levels (sphingomyelin \[SM\] and phosphatidylethanolamine \[PE\]) ([Figure S2](#mmc1){ref-type="supplementary-material"}L). Cholesterol precursor levels were altered in accordance with the enzymatic target of the different compounds ([Figures S2](#mmc1){ref-type="supplementary-material"}M--S2O); atorvastatin reduced desmosterol and lathosterol levels, AY9944 reduced desmosterol and lathosterol levels and increased 7DHC levels, and T0901317 and efavirenz had minor (slightly inhibitory) effects on precursor levels. 24-Hydroxycholesterol (a direct downstream metabolite of cholesterol) was increased in media from efavirenz-treated neurons, was decreased in AY-9944-treated samples, and was unaltered in atorvastatin- and T0901317-treated neurons ([Figure S2](#mmc1){ref-type="supplementary-material"}P). Surprisingly, however, although these compounds behaved as expected, only AY-9944 (that only had minor effect on pTau, [Figure 2](#fig2){ref-type="fig"}C) reduced free cholesterol levels ([Figure 2](#fig2){ref-type="fig"}D). It is important to note that our iPSC-derived neurons are cultured in media without an exogenous source of cholesterol, and thus neuronal cholesterol levels cannot be compensated by enhanced uptake from the media. Whereas changes in free cholesterol levels were not detected for most compounds, all compounds significantly reduced the levels of total cholesterol (free + esterified cholesterol) ([Figure 2](#fig2){ref-type="fig"}E) through a strong reduction of CE ([Figure 2](#fig2){ref-type="fig"}F). This finding suggests that conversion of CE to cholesterol compensates for the loss of cholesterol through inhibition of synthesis or induction of export, and reductions in CE, not free cholesterol, mediate the effects of the different compounds on pTau. In line with this observation, direct inhibition of cholesterol esterification by the ACAT inhibitors avasimibe (aka CI-1011) ([Figures 2](#fig2){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}Q--S2V) ([@bib26], [@bib27], [@bib36]) or K604 ([Figure 2](#fig2){ref-type="fig"}G) also reduced pTau. Exogenous addition of cholesterol and CE (in the form of LDL) increased pThr231Tau/tTau ([Figure 2](#fig2){ref-type="fig"}H) levels. Together, our data show that CE regulate pTau levels in human FAD neurons. We investigated the mechanisms underlying CE-dependent regulation of pTau in more detail.Figure 2The Effect of Statins on pTau Is Mediated by Cholesteryl Esters(A) Overview of the mevalonate pathway and inhibitors used in this study.(B) APP^dp^1-6 neurons were treated with DMSO or atorvastatin (10 μM) for 5 days. For indicated conditions, mevalonate (MVA, 0.5 mM), mevalonate-5-phosphate (MVP, 0.5 mM), or mevalonate-5-pyrophosphate (MVA-5PP, 1 mM) was added to the media at a single dose at t = 0 (mean ± SEM, n ≥ 3).(C) APP^dp^1-6 neurons were treated with inhibitors of specific steps in the mevalonate pathway; atorvastatin (10 μM), FTI-227 (10 μM), GGTI (10 μM), YM-53601 (20 μM), AY-9944 (10 μM), fatostatin (20 μM), 24-hydroxycholesterol (10 μM), T0901317 (10 μM), rosiglitazone (50 μM), GW501516 (10 μM), and efavirenz (10 μM). pThr231Tau/tTau levels were determined by ELISA (mean ± SEM, n ≥ 3).(D--F) APP^dp^1-6 neurons were treated with atorvastatin (10 μM), AY-9944 (5 μM), T0901317 (10 μM), or efavirenz (10 μM) for 3 days and lipid analysis was performed to measure (D) free cholesterol (mean ± SEM, n ≥ 8), (E) total cholesterol (mean ± SEM, n ≥ 4), and (F) CE (mean ± SEM, n ≥ 8).(G) pThr231Tau/tTau levels after 5-day treatment of APP^dp^1-6 neurons with avasimibe (10 μM) or K604 (25 μM) (mean ± SEM, n ≥ 3).(H) Treatment of APP^dp^1-6 neurons with LDL (25 μg/mL) (mean ± SEM, n ≥ 3).See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Regulation of pTau by CE Is Correlated with, but Independent of, APP and Aβ {#sec2.3}
---------------------------------------------------------------------------

APP^dp^ neurons have an extra copy of APP and increased levels of both Aβ and pTau ([@bib29], [@bib47]). To understand the relationship between APP copy number, Aβ, and CE-dependent regulation of pTau in more detail, we also treated NDC neurons with the normal two copies of APP with cholesterol-targeting drugs. Simvastatin, atorvastatin, efavirenz, and the ACAT inhibitors avasimibe and K604 all reduced pThr231Tau/tTau in the NDC neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}A). For simvastatin, we further tested an extensive dose range and found that it reduced pThr231Tau/Tau in NDC neurons in a similar dose-dependent manner as in APP^dp^ neurons ([Figure 3](#fig3){ref-type="fig"}A). A single dose of statin or efavirenz also decreased pThr231Tau/tTau in sporadic AD (SAD) patient- and non-demented control (NDC) neurons ([Figures 3](#fig3){ref-type="fig"}B, 3C, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C). pThr231Tau/tTau was also reduced by simvastatin in cultured hippocampal mouse neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Together, these data indicate that CE-dependent regulation of pTau is conserved across individual patients and healthy subjects (and even across species) and is not dependent on baseline APP copy number.Figure 3pTau and Aβ Are Co-regulated by CE through Separate Pathways(A) Dosage effect of simvastatin treatment on pThr231Tau/tTau on non-demented control (NDC) neurons (CV 151 line).(B and C) Effect of simvastatin (10 μM) (B) or efavirenz (10 μM) treatment (C) on pThr231Tau/tTau in neuronal lines from SAD and NDC subjects (mean ± SEM, number of individual patients indicated in bars).(D) Secreted Aβ levels from APP^dp^1-6 neurons treated with atorvastatin (10 μM) for 5 days normalized to DMSO-treated neurons (mean ± SEM, n ≥ 3).(E) Correlation of Aβ42 and pThr231Tau/tTau levels in atorvastatin-treated neurons at different time points, dosages, and in different cell lines (light circles, APP^dp^1-6; dark circles, APP^dp^2-1). CC, correlation coefficient.(F and G) Characterization of APP^null^ line. (F) Western blot with antibodies against APP in isogenic APP^dp^ (line APP^dp^ 2-1) and APP^null^ (line APP^dp^1KO). Full-length APP (FL) and APP CTF are no longer detected in the APP^dp^1^null^ line. The FL-APP (22C11) cross reacts with APLP2 explaining the remaining signal in the FL-APP (22C11 blot). (G) ELISA analysis shows an absence of Aβ40 and Aβ42 in conditioned media from the APP^null^ line. Positive control is APP^dp^1-2, negative control is unconditioned media. The detection antibody for the ELISA is 6E10, as indicated in (F).(H) Dosage effect of simvastatin treatment on pThr231Tau/tTau on neurons with indicated genotypes (mean ± SEM, n ≥ 3). Isogenic knockouts used were in an APP^dp^ patient genetic background (lines APP^dp^1-2 \[^dp^\] and APP^dp^1KO \[^null^\] or non-demented control \[NDC\] genetic background \[CV line 151 (wild-type \[WT\])\] and IB6 \[^null^\]).Mean ± SEM; n ≥ 5. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

In addition to our findings on pTau, CE reduction has previously been reported to reduce Aβ levels ([@bib25], [@bib26], [@bib56]), and Aβ secretion from our iPSC-derived neurons was also decreased by statins ([Figure 3](#fig3){ref-type="fig"}D). We observed a strong correlation between Aβ42 secretion and pThr231Tau/tTau in response to atorvastatin treatment across time points and drug doses ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}E). To test whether the effect of CE on pTau was mediated by alterations in APP processing and/or the reduction of Aβ, we generated an isogenic APP^null^ line in an APP^dp^ patient genetic background ([Figures 3](#fig3){ref-type="fig"}F, 3G, and [S3](#mmc1){ref-type="supplementary-material"}F--S3H). No APP expression or Aβ secretion was detected in the APP^null^ neurons ([Figures 3](#fig3){ref-type="fig"}F and 3G). pThr231Tau/tTau levels were reduced at baseline in the APP^null^ neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}I). Interestingly, in these APP^null^ neurons, simvastatin still reduced pThr231Tau/tTau in a dose-dependent manner identical to that of its isogenic control lines ([Figure 3](#fig3){ref-type="fig"}H). Similarly, simvastatin reduced pThr231Tau/tTau the same in a previously generated isogenic set of NDC (APP^wt^) and APP^null^ neurons (CV line 151 and IB6) ([@bib20]) ([Figure 3](#fig3){ref-type="fig"}H). Together, these data show that CE regulate both pTau and Aβ, but regulation of pTau by CE is APP- and Aβ-independent.

The Effect of CE on Aβ Is Mediated by a Cholesterol-Binding Domain in APP {#sec2.4}
-------------------------------------------------------------------------

To understand the respective pathways by which CE regulate pTau and Aβ, and to verify that these pathways are indeed separate, we first studied the relationship between CE and Aβ secretion in more detail. We hypothesized that the effect of CE on Aβ secretion could be mediated by a recently identified cholesterol-binding domain in APP β-CTF ([@bib4]). We used CRISPR/Cas9 to mutate the cholesterol-binding domain in the endogenous APP locus ([Figures 4](#fig4){ref-type="fig"}A--4C, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B) and created two mutations that had previously been shown to abolish APP β-CTF-cholesterol interactions ([@bib4]), APP E693A and APP F691A+E693A. We observed that Aβ42 secretion in these isogenic APP-Δcholesterol lines was reduced under steady state conditions ([Figure 4](#fig4){ref-type="fig"}D) indicating that the cholesterol-binding domain affects APP processing and Aβ secretion. More importantly, atorvastatin treatment ([Figure 4](#fig4){ref-type="fig"}E) did not affect Aβ42 secretion in these neurons indicating that the effect of lowering CE on Aβ42 is mediated by the cholesterol-binding domain in APP. While Aβ secretion was no longer regulated by atorvastatin in these neurons, atorvastatin still decreased pT231Tau/tTau ratio (in an identical manner as in their isogenic wild-type controls) ([Figure 4](#fig4){ref-type="fig"}F), again confirming that the effect of CE on pTau and the effect of CE on Aβ are regulated through two separate pathways. We next sought to determine how CE regulate pTau.Figure 4Regulation of Aβ by CE Is Mediated by a Cholesterol Binding Domain in APP(A) Schematic representation of the transmembrane domain of APP with amino acids essential for cholesterol binding indicated in yellow.(B) Schematic overview of the gene-editing strategy to generate APP-Δcholesterol lines. Green indicates amino acid sequence. Red arrow indicates CRISPR/Cas9 cut site.(C) Sequencing results verifying correct incorporation of desired mutations in the APP-Δcholesterol lines. Two E693A (line 3D9 and 2B2) and one F691A+E693A line (line D12) were generated, as well as two non-gene-edited, but clonally expanded, WT lines (B10 and B11).(D--F) Measurements made using APP-Δcholesterol neurons with the following genotypes: WT (average from 2 independent lines), E693A (2 independent lines), and F691A+E693A (1 line) (mean ± SEM, n ≥ 3 per line). (D) Relative secreted Aβ42 levels in conditioned media from purified CD184^−^, CD44^−^, and CD24^+^ neurons (mean ± SEM, n ≥ 3 per line). (E) Relative secreted Aβ42 in response to atorvastatin treatment (10 μM, 3 days) (mean ± SEM, n ≥ 3 per line) (F) pThr231Tau/tTau in response to atorvastatin treatment (10 μM, 3 days) in APP-Δcholesterol neurons (mean ± SEM, n ≥ 3 per line).See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

The Effect of CE on pTau Levels Is Mediated by the Proteasome {#sec2.5}
-------------------------------------------------------------

Previous reports indicate that accumulation of pTau in FAD neurons can be downstream of altered proteostatic regulation of (p)Tau ([@bib47]). To assess whether CE affect the proteostatic regulation of pTau, we performed quantitative western blot on APP^dp^ neurons treated with different CE-targeting drugs. In addition to a reduction of pS396/S404Tau and pS202/T205Tau, CE reduction also reduced total Tau ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}A). The reduction of pTau and total Tau by our treatments was not explained by a specific loss of neurons in the cultures ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5D). The reduction of both pTau as well as tTau could indicate a proteostatic regulatory event, rather than altered Tau phosphorylation and dephosphorylation events. This was further substantiated by the finding that activity of GSK3β (a major Tau kinase) was not affected by statin-mediated CE reduction ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Next, we attempted to rescue the effect of CE reduction on pThr231Tau/tTau with inhibitors of phosphatase activity (okadaic acid), proteasomal (MG132), and/or or lysosomal and autophagosomal (chloroquine) degradation ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}F--S5M). Only proteasomal inhibition abrogated the decrease in pThr231Tau/tTau ratio induced by atorvastatin ([Figures 5](#fig5){ref-type="fig"}C and 5N), indicating that the effect of CE on pTau is mediated by the proteasome. Interestingly, in addition to cholesterol-synthetic genes, we found that the 26S proteasome regulatory subunit 7 (PSMC2) was also upregulated after statin treatment in NDC neurons ([Figure S2](#mmc1){ref-type="supplementary-material"}D; [Table S2](#mmc1){ref-type="supplementary-material"}). We validated by western blot in APP^dp^ neurons that statin treatment increased the levels of proteasomal subunit PSMC2 ([Figures 5](#fig5){ref-type="fig"}D and 5E). Levels of another proteasome subunit, proteasome subunit beta type-5 (PSMβ5) in the core of the proteasome, were also increased ([Figures 5](#fig5){ref-type="fig"}D and 5E). This statin-dependent increase in proteasome levels is not mediated by transcriptional upregulation of proteasomal subunits ([Figure S5](#mmc1){ref-type="supplementary-material"}N). Using a proteasome activity binding probe ([@bib5], [@bib38]), we found that CE reduction through either statins or efavirenz increased total cellular proteasome activity in both APP^dp^ and NDC neurons ([Figures 5](#fig5){ref-type="fig"}F--5I). The effect of CE on proteasome function was not mediated by mechanistic target of rapamycin (mTor) ([Figures S5](#mmc1){ref-type="supplementary-material"}O--S5Q). Together, our data show that reducing neuronal CE enhances proteasome levels, increases total cellular proteasome activity, and induces the proteasomal degradation of pTau indicative of a CE-proteasome-Tau axis.Figure 5Regulation of pTau by CE Is Mediated by the Proteasome(A and B) The effect of CE lowering treatments on Tau levels and Tau phosphorylation as assessed by western blot (A), quantified in (B) (mean ± SEM, n ≥ 3). Image is a composite of different loading positions on same blot, stitch is indicated by vertical line.(C) pThr231Tau/tTau levels in APP^dp^1-6 neurons co-treated with atorvastatin (10 μm) and a lysosomal inhibitor (chloroquine, CQ 25 μM), a phosphatase inhibitor (okadaic acid, 1.25nM) or a proteasome inhibitor (MG132, 5 μM) for 3 days as measured by ELISA (mean ± SEM, n ≥ 3).(D and E) APP^dp^1-6 neurons were treated for 3 days with DMSO, simvastatin (10 μM) or atorvastatin (10 μM) and levels of proteasome subunits PSMC2 and PSMβ1/5 were assessed by western blot (D). Quantified in (E) (mean ± SEM n ≥ 3). PSMβ1/5/actin image is a composite of different loading positions on same blot, stiches are indicated by vertical line.(F--I) APP^dp^1-6 (F and G) or NDC CV4a (H and I) neurons were treated for 3 days with DMSO, simvastatin (10 μM), atorvastatin (10 μM), or efavirenz (10 μM) and incubated with a proteasome activity binding probe (ABP) for 1 h. Cells were lysed, run on SDS-page, and ABP fluorescence from the gel was determined (mean ± SEM, n ≥ 5). (G) Quantification of the western blots from (F). (I) Quantification of western blots from (H). Images are composite of different loading positions on same blot, stiches are indicated by vertical lines.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

CYP46A1 Activation Is a Neuron-Specific CE-Reducing Approach that Is Better Tolerated by Astrocytes Than HMGCR Inhibitors (Statins) {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------------------

Our data indicate that neuronal CE are a potential therapeutic target to activate the proteasome and prevent aberrant pTau accumulation in AD. To identify possible adverse effects of candidate CE-lowering strategies on other non-neuronal brain cells, we tested the toxicity of selected compounds on iPSC-derived astrocytes. All iPSC-derived astrocytes displayed radial morphology of astrocytes and expressed the glial marker GFAP, while the neural stem cell marker SOX2 was not expressed ([Figure 6](#fig6){ref-type="fig"}A). We concentrated on two different drugs that currently have Food and Drug Administration (FDA) approval for other indications, statins (to lower cholesterol synthesis) and efavirenz (that activates the neuron-specific enzyme CYP46A1). Already, at low concentrations, simvastatin and atorvastatin induced major astrocyte cell death ([Figures 6](#fig6){ref-type="fig"}B, 6C, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B), whereas efavirenz did not affect astrocyte viability even at high doses ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}C). 24-Hydroxycholesterol was not detected in astrocyte media before or after treatment with efavirenz. Efavirenz increased 24-hydroxycholesterol secretion from APP^dp^ and APP^null^ neurons in a dose-dependent manner that correlated well with its effect on pThr231Tau/tTau in these neurons ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}D). Together, these data show that allosteric activation of CYP46A1 is a neuron-specific CE- and pTau-lowering treatment with less adverse effects on astrocytes and provides a therapeutic approach to reduce pTau accumulation in early AD-neurons.Figure 6CYP46A1 Activation Is a Neuron-Specific CE-Reducing Approach that Is Better Tolerated by Astrocytes(A) iPSC-derived astrocytes were fixed and stained with indicated antibodies. Scale bar, 10 μm.(B--D) iPSC-derived APP^dp^1-6 astrocytes were treated for 3 days with increasing concentrations of (B) atorvastatin, (C) simvastatin, and (D) efavirenz, and viability was measured (cell titer glo). Astrocytic viability (blue line) was plotted against results from [Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}A for statins (neuronal viability and pThr231Tau/Tau ratio). For efavirenz, dose responses to measure pThr231Tau/tTau and neuronal viability were performed in APP^dp^1-6 neurons (mean ± SEM, n ≥ 3--6).(E) Model depicting the relationship between CE, pTau, and Aβ in early AD neurons. Statins reduce CE levels through inhibition of the cholesterol-synthetic pathway, while efavirenz enhances the turnover of cholesterol to 24-hydroxycholesterol that causes conversion of CE to cholesterol and a reduction in CE. Reduced CE cause proteasomal upregulation and degradation of pTau. In a correlated, but independent pathway, CE regulate APP processing and Aβ generation.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Here, we used AD-patient iPSC-derived neurons in a phenotypic drug screen to identify compounds that reduce aberrant pTau accumulation in FAD neurons ([@bib29], [@bib47], [@bib50], [@bib53]). From a library of \>1,600 compounds, we successfully identify 42 compounds that reduced pTau levels, including six previously reported modulators of pTau and 36 novel pTau targeting compounds ([Figure 1](#fig1){ref-type="fig"}). From the 42 identified compounds, we selected cholesterol-targeting compounds (statins) to study in more detail. Cholesterol metabolism has previously been implicated in AD ([@bib15], [@bib57]) and CE, the esterified storage products of cholesterol, accumulate in AD patient brains ([@bib11]) and in APP-transgenic mice ([@bib11], [@bib67], [@bib70]). We show that reducing CE, through a number of mechanistically different drugs, reduces levels of pTau at multiple phosphorylation epitopes in both FAD, SAD, and NDC subject neurons. CE have previously also been shown to regulate APP processing and Aβ generation ([@bib25], [@bib26], [@bib56]), and we confirmed that CE also regulate Aβ secretion from human iPSC-derived AD patient neurons. Interestingly, we find that the effect of CE on Aβ is independent of the effect of CE on pTau ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), and pTau and Aβ are thus co-regulated by CE through independent pathways. Similar co-regulation of Aβ and Tau through independent pathways have recently been shown for ApoE ([@bib68]) and the retromer complex ([@bib72]). These findings, together with our findings, reinforce the notion that common upstream (pathogenic) pathways in SAD, such as CE, can drive increased levels of pTau and Aβ through separate pathways ([@bib66]), rather than only through a direct linear pathway directly from Aβ to Tau.

Pathways that Mediate the Effect of CE on pTau and Aβ {#sec3.1}
-----------------------------------------------------

We investigated the separate pathways that underlie CE-dependent regulation of pTau and Aβ, respectively, in early AD neurons. We find that the effect of CE on Aβ is mediated by a cholesterol binding-site in APP, whereas the effect of CE on pTau is mediated by the proteasome. Surprisingly, in our system, we did not observe significant differences in free cholesterol levels for the treatments that reduced CE, Aβ, and pTau. As also previously observed ([@bib56]), these data indicate that CE mediates the effect of cholesterol-targeting drugs on Aβ. We show that the effect of CE on Aβ is mediated by a domain in APP that has previously been shown to bind cholesterol ([@bib4]), possibly suggesting that this cholesterol-binding domain can also sense CE. Alternatively, localized reductions in cholesterol in specific domains such as lipid rafts ([@bib18]), specific organelles, or localized changes in *de novo* synthesized cholesterol under the detection limit of our measurements could mediate the effect of statins on APP processing via the APP-cholesterol binding domain. In regard to CE-dependent regulation of pTau, we find that reduction of CE increases the level of proteasomal subunits, overall proteasomal activity, and proteasomal degradation of pTau (see model [Figure 6](#fig6){ref-type="fig"}E). This indicates a neuronal CE-proteasome-pTau axis that regulates turnover of neuronal pTau. The effect of CE on proteasome levels is not mediated by enhanced transcription of proteasomal subunits, and the exact mechanism by which CE control proteasomal activity needs to be further determined. Interestingly, in other model systems, lipid droplets (the storage site of CE) have been shown to be active signaling organelles that regulate proteasome activity ([@bib3], [@bib33]). The neuronal proteasome also associates with plasma membranes ([@bib58]), offering another possible neuron-specific site of convergence between CE and the proteasome. CE-dependent regulation of the proteasome is also relevant for other neurodegenerative diseases in which altered cholesterol-homeostasis and protein aggregation occurs such as Niemann-Pick type C and Huntington disease ([@bib31]). Another open issue is why pTau is regulated by CE. Direct coupling of CE to pTau levels could indicate a pathway that coordinates the speed of Tau-regulated axonal transport or growth, with the availability of (stored) neuronal cholesterol required for membrane growth or synapse formation. Overall, our data here indicate that CE regulate pTau and Aβ by two separate pathways and suggests that CE could be an upstream driver of both Aβ secretion and pTau accumulation.

CE and AD {#sec3.2}
---------

Our findings provide a mechanistic explanation for how changes in CE, induced by APP mutations or SAD genetic risk variants in APP ([@bib11], [@bib67], [@bib70]) could contribute to Tau pathology. Interestingly, CE production is overactive in human SAD fibroblasts ([@bib54]) and APOE, the major genetic risk factor for SAD, acts as a CE transporter in brain ([@bib39], [@bib45], [@bib46]). Our findings in human iPSC-derived AD neurons indicate that alterations in neuronal CE could drive pTau accumulation and are supported by previous *in vivo* observations in mouse models showing that statins reduce NFT load in animal models of tauopathy ([@bib7]), and genetic inhibition of cholesterol esterification by ACAT1 reduces tauopathy in an AD-mouse model ([@bib65]), indicating that the interactions between CE and Tau are conserved in the adult (mouse) brain. We describe several pharmaceutical strategies to reduce CE in early AD neurons including LXR target gene-mediated cholesterol export, conversion of cholesterol to hydroxycholesterol by CYP46A1 activators, and direct inhibition of cholesterol esterification by ACAT inhibitors. In humans, long-term statin usage has been shown to correlate with reduced AD incidence in some studies ([@bib61], [@bib62], [@bib74]), although the underlying mechanisms have been debated. Statins also reduce pTau levels in CSF from AD patients ([@bib59]). Here, we show that the effects of statins on pTau can be directly mediated by CE and are not merely a consequence of altered APP processing or peripheral effects of cholesterol-targeting drugs. However, our data do not indicate that statins are the best candidate drugs for targeting Tau accumulation in AD. Statins affect the levels of pTau in human neurons only at relatively high concentrations ([Figure 1](#fig1){ref-type="fig"}) unlikely reached in human brain ([@bib6]) and have strong adverse effects on human astrocytes at these high concentrations ([Figure 6](#fig6){ref-type="fig"}). We cannot exclude the possibility that *in vivo* statins lower neuronal CE through indirect effects on astrocytic cholesterol and/or CE production, but our data do indicate that additional potency could be gained from enhanced targeting of neuronal CE. We show that allosteric activators of CYP46A1 could provide a neuron-specific approach to reduce CE and pTau in early AD neurons. Regulation of pTau by CYP46A1 is also conserved in adult (mice) brains where genetic inhibition of CYP46A1 enhances abnormal phosphorylation of Tau ([@bib17]), and overexpression of CYP46A1 in transgenic Tau mice rescues cognitive decline ([@bib10]).

We targeted CYP46A1 through allosteric activation by the small molecule efavirenz ([@bib1]) and show that efavirenz reduces pTau in early human AD neurons without affecting astrocyte viability. Efavirenz, originally marketed as an HIV-medication (brand name Sustiva), has recently also been shown to reduce amyloid pathology in AD mice ([@bib43]) indicating that efavirenz could possibly be repurposed for AD. However, when given to HIV patients at high doses, efavirenz has significant adverse effects that include neurotoxicity ([@bib2]). Major adverse effects were not observed in mice at lower concentrations of efavirenz that sufficed to alter brain cholesterol metabolism and reduce amyloid pathology, indicative of an appropriate therapeutic window ([@bib43]). Other allosteric activators of CYP46A1 have also recently been identified ([@bib42]). The *in vivo* data of CYP46A1 activators on inhibitors of amyloid pathology ([@bib43]), together with our findings that CYP46A1 activators reduce Tau accumulation in human AD neurons, support the development of allosteric activators of CYP46A1 as therapies for AD.

In conclusion, using high-throughput phenotypic screening, we identified \>40 FDA-approved drugs with diverse biological targets that reduce pTau in early AD neurons. By pathway mapping, we identify a CYP46A1-CE-Tau axis as a druggable pathway in early AD. We find that reducing CE potently decreases neuronal pTau levels through proteasomal upregulation and degradation of pTau in an APP- and Aβ-independent manner. In a separate pathway, Aβ secretion is regulated by CE through a cholesterol-binding domain in APP. We find that allosteric activation of CYP46A1 is a neuron-specific CE-lowering strategy that is well tolerated by human astrocytes. Together, our data indicate CE as a dual upstream regulator of pTau and Aβ, and we propose CE-reduction, particularly through CYP46A1 activation, as a therapeutic approach to independently reduce accumulation of pTau and Aβ in AD patients.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**anti-total Tau clone 7 (IF 1:100, WB 1:1000)EMD MilliporeMAB2239 RRID:[AB_1587549](nif-antibody:AB_1587549){#intref0010}anti-pS202/T205 Tau (IF 1:50, WB 1:500)Peter DaviesCP13 RRID:[AB_2314223](nif-antibody:AB_2314223){#intref0015}anti-pS396/S404 Tau (IF 1:50, WB 1:500)Peter DaviesPHF1 RRID:[AB_2315150](nif-antibody:AB_2315150){#intref0020}anti-pThr231 conformational (IF 1:50)Peter DaviesTG3 RRID:[AB_2716726](nif-antibody:AB_2716726){#intref0025}anti-MAP2 (IF 1:1000)Abcamab5392 RRID:[AB_2138153](nif-antibody:AB_2138153){#intref0030}anti-neurofilament 131/132 (IF 1:5000)CovanceSMI31 RRID:[AB_2314901](nif-antibody:AB_2314901){#intref0035}anti-Actin clone C4 (WB 1:50,000)EMD MilliporeMAB1501 RRID:[AB_2223041](nif-antibody:AB_2223041){#intref0040}anti-APLP2 (WB 1:1000)Calbiochem/Millipore171617 RRID:[AB_565357](nif-antibody:AB_565357){#intref0045}anti-APP A4 clone 22C11 (WB 1:1000)EMD MilliporeMAB348 RRID:[AB_94882](nif-antibody:AB_94882){#intref0050}anti-APP C-Terminal (WB 1:500)EMD Millipore171610 RRID:[AB_211444](nif-antibody:AB_211444){#intref0055}anti-total Tau (WB 1:1000)SigmaT6402 RRID:[AB_261728](nif-antibody:AB_261728){#intref0060}anti-histone 3 clone (WB 1:1000)Upstate/Millipore06-755 RRID:[AB_11211742](nif-antibody:AB_11211742){#intref0065}anti-LC3b (WB 1:1000)Novus biologicalsNB600-1384 RRID:[AB_669581](nif-antibody:AB_669581){#intref0070}anti-ubiquitin (WB 1:250)EMD MilliporeMAB1510 RRID:[AB_2180556](nif-antibody:AB_2180556){#intref0075}anti-Phospho-4E-BP1 (Thr37/46) (WB 1:1000)Cell SignalingAntibody \#9459 RRID:[AB_330985](nif-antibody:AB_330985){#intref0080}anti-p70 S6 Kinase Antibody (WB 1:1000)Cell SignalingAntibody \#9202 RRID:[AB_331676](nif-antibody:AB_331676){#intref0085}anti-4E-BP1 Antibody (WB 1:1000)Cell SignalingAntibody \#9452 RRID:[AB_331692](nif-antibody:AB_331692){#intref0090}anti-Phospho-p70 S6 Kinase (Thr389) (WB 1:1000)Cell Signaling108D2, Antibody RRID:[AB_2269803](nif-antibody:AB_2269803){#intref0095}Anti-PSMC2 (D5T1T)) (WB 1:1000)Cell Signaling\#14395 RRID:[AB_2752224](nif-antibody:AB_2752224){#intref0100}anti-PSMB5 (WB 1:1000)Enzo LifesciencesCat\# BML-PW8895 RRID: [AB_10540901](nif-antibody:AB_10540901){#intref0105}anti-GAPDH (WB 1:1000)Life TechnologiesAM4300 RRID: [AB_2536381](nif-antibody:AB_2536381){#intref0110}anti-Nestin Clone 25/NESTIN (RUO) (1:500)BD611658 RRID:[AB_399176](nif-antibody:AB_399176){#intref0115}anti-S100b (1:500)Proteintech15146-1-AP RRID:[AB_2254244](nif-antibody:AB_2254244){#intref0120}anti-Vamp2 (aka synaptobrevin 2) (1:1000)synaptic systems104 211 RRID:[AB_887811](nif-antibody:AB_887811){#intref0125}anti- Syntaxin 1 (1:5000)Gift from the Thomas Sudhof labpolyclonal \#I379anti-Synaptotagmin (1:2000Gift from the Thomas Sudhof labpolyclonal \#W855Tra-181-647BD560124 RRID:[AB_1645449](nif-antibody:AB_1645449){#intref0130}CD184-APC (FC 1:10)BD555976 RRID:[AB_398616](nif-antibody:AB_398616){#intref0135}CD44-PE (FC 1:10)BD555479 RRID:[AB_395871](nif-antibody:AB_395871){#intref0140}CD24-PECy7 (FC 1:40)BD561646 RRID:[AB_10892826](nif-antibody:AB_10892826){#intref0145}CD271-PEBD557196 RRID:[AB_396599](nif-antibody:AB_396599){#intref0150}**Chemicals, Peptides, and Recombinant Proteins**T0901317SigmaT2320GW501516Enzo life sciences89150-762RosiglitazoneSigmaR2408Atorvastatin calcium saltSigmaPZ001SimvastatinSigmaS6196RosuvastatinSigmaSML1264FluvastatinSigmaSML0038MevastatinTocris1526LovastatinSigmaPHR1285Mevalonolactone (Mevalonic Acid)SigmaM4777(R)-Mevalonic acid 5-pyrophosphoate tetralithium saltSigma77631Mevalonic acid 5-phosphate thrilithium salt hydrateSigma79849Methyl-β-cyclodextrinSigmaC4555YM-53601Cayman Chemicals18113AY 9944 dihydrochlorideTocris1639FTI-227 trifluoroacetate saltSigmaF9803GGTI-298 trifluoracetate salt hydrateSigmaG5169Fatostatin hydrobromideSigmaF893224(S)-hydroxycholesterolCayman Chemicals10009931chloroquine diphosphate saltSigmaC6628MG-132 (InSolution)Calbiochem37391CholestaneSigma-AldrichC8003*N*-Methyl-*N*-(trimethylsilyl)trifluoroacetamide (MSTFA)ThermoFisherTS48910dry pyridineSigma-Aldrich270970sodium hydroxide solution 10M (BioUltra)Sigma Aldrich72068Ri, Y-27632 dihydrochlorideAbcamab120129SB431542Stemgent4-0010NogginR&D3344-NGProteasome activity probe 1[@bib5], [@bib14]N/ASCR7Excess BioscienceM60082-2L-755,507SigmaSML1362K-604SigmaSML1837**Critical Commercial Assays**Phospho(Thr231)/Total Tau KitMSDK15121D-3V-PLEX Ab Peptide Panel 1 (6E10) Kit (25 Plate)MSDK15200E-424(S)-Hydroxycholesterol ELISA kitEnzoADI-900-210-0001CellTiter-Glo® Luminescent Cell Viability AssayPromegaG7571CellTiter 96® AQueous One Solution Cell Proliferation AssayPromegaG3580Pierce LDH Cytotoxicity Assay KitThermo Fisher Scientific88954Amplex Red Cholesterol Assay KitThermoFisher ScientificA12216LipidyzerSciexN/A**Experimental Models: Cell Lines**CV (NPC)[@bib22]RRID:CVCL_1N86151 (CV WT) (iPSC, NPC)[@bib20]RRID: CVCL_UI49IB6 (APP^null^ in CV background) (iPSC, NPC)[@bib20]RRID:CVCL_UI22B10 (CV Wt) (iPSC, NPC)This PaperRRID:CVCL_VR50B11 (CV Wt) (iPSC, NPC)This PaperRRID:CVCL_VR513d9 (CV APP E693A) (iPSC, NPC)This PaperRRID:CVCL_VR532b2 (CV APP E693A) (iPSC, NPC)This PaperRRID:CVCL_VR52D12 (CV APP E693A+F691A) (iPSC, NPC)This PaperRRID:CVCL_VR54APP^dp^1.2 (iPSC, NPC)[@bib29]RRID:CVCL_EJ97APP^dp^ 1.6 (iPSC, NPC)[@bib29]RRID:CVCL_EJ96APP^dp^ 2.1 (iPSC, NPC)[@bib29]RRID:CVCL_EJ99APP 1KO (APP^null^ in APP^dp^1.2 background) (iPSC, NPC)This PaperRRID: CVCL_UI23NDC1 (M) NPC[@bib29], [@bib71]RRID:CVCL_EJ84NDC2 (M) NPC[@bib29], [@bib71]RRID:CVCL_EJ87NDC3 (M) NPC[@bib71]RRID: CVCL_UB88NDC4 (M) NPC[@bib71]RRID: CVCL_UB89NDC5 (M) NPC[@bib71]RRID: CVCL_UB90SAD1 (F) NPC[@bib29], [@bib71]RRID: CVCL_EJ90SAD2 (M) NPC[@bib29], [@bib71]RRID: CVCL_EJ93SAD3 (M) NPC[@bib71]RRID: CVCL_UB91SAD4 (F) NPC[@bib71]RRID: CVCL_UB92SAD5 (F) NPC[@bib71]RRID: CVCL_UB93SAD6 (M) NPC[@bib71]RRID: CVCL_UB94SAD7 (M) NPC[@bib71]RRID: CVCL_UB95**Experimental Models: Organisms/Strains**C57BL/6J MiceJackson Laboratory000664**Oligonucleotides**Repair Oligos used to make CRISPR mutant lines See [Table S6](#mmc1){ref-type="supplementary-material"}This PaperN/APrimers for amplification of APP Cholesterol Binding region See [Table S6](#mmc1){ref-type="supplementary-material"}This PaperN/AAPP Cholesterol binding region genomic DNA Sequencing Primer See [Table S6](#mmc1){ref-type="supplementary-material"}This PaperN/AqPCR Primers See [Table S6](#mmc1){ref-type="supplementary-material"}This PaperN/A**Recombinant DNA**G7A: TOPO guide RNA plasmid for Generating cholesterol-mutant lines with target sequence: 5′GTGTTCTTTGCAGAAGATGTGGG3′This PaperN/AGuide RNA plasmid for generating APP^null^ line in APP^dp^-patient background with target sequence: 5′GGAGATCTCTGAAGTGAAGATGG3′This PaperN/ACMV::Cas9-2A-eGFPSigma-AldrichCAS9GFPP-1EACYP46A1-pDESTlentiFGA1.0.This PaperN/AGFP-only plasmid-pDESTlentiFGA1.0. (pSyn(pr)EGFPLL3.7)This PaperN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Larry Goldstein (<lgoldstein@ucsd.edu>).

All cell line requests will require a material transfer agreement (MTA).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cultured Mouse Cortical Neurons {#sec4.3.1}

Primary cortical neurons were cultured from postnatal day zero C57BL/6J pups. Briefly, pups were decapitated into Hanks' medium without Ca^2+^ and Mg^2+^, and cortices were dissected in Neurobasal-A medium supplemented with 10 mm HEPES. After dissection, cortices were trypsinized for 25 min at 37°C and dissociated. Neurons were plated in Neurobasal-A with B27 supplement and drug-treatment was performed after 2 weeks.

### Human iPSC Derived Cell lines {#sec4.3.2}

#### Cell lines {#sec4.3.2.1}

Novel NPC lines were generated from previously established iPSC lines. The APP^dp^ AD-patient NPC lines used in this study are; APP^dp^1-6 (derived from iPSC-line APP^dp^1.1 in [@bib29]), APP^dp^1-2 (derived from iPSC-line APP^dp^1.2 in [@bib29]) and APP^dp^2-1 (derived from iPSC-line APP^dp^2.3 in [@bib29]). See [@bib29] for generation and characterization of these APP^dp^ iPSC lines and patient details. SAD and NDC NPC lines used are CV4a, SAD1, SAD2, SAD5, SAD5, SAD7, NDC1, NDC2, NDC4 and NDC5 described in [@bib71];

To generate isogenic APP knockout iPSCs in an APP^dp^ patient 1 background, iPSC-line APP^dp^1-2 was gene edited to generate the iPSC and NPC-line APP^dp^1KO. To generate isogenic APP knockout lines in wild-type (Craig Venter, CV) background, iPSC-line CVB ([@bib22]) was gene edited to generate IPSC and NPC-line IB6 (CV APP^null^) and 151 (CV wt) ([@bib20]). To generate isogenic Δcholesterol APP mutants the iPSC-line CVB ([@bib22]) was gene edited to generate iPSC and NPC-lines B10 (wt), B11 (wt), 3D9 (homozygous E693A), 2B2b (homozygous E693A) and D12 (homozygous F691A+E693A).

#### iPSC genome editing {#sec4.3.2.2}

Generation of isogenic APP knockout lines in a wild-type (CV iPSC) background, IB6 (APP knockout) and 151 (wt) was described previously ([@bib20]). For gene-editing, iPSCs were pretreated with 10uM Rock inhibitor (Ri, Y-27632 dihydrochloride, Abcam) 2 hours prior to nucleofection. iPSC's were dissociated with Accutase and filtered through 100uM filter and spun down at 1000rpm for 5 minutes. Two million cells were nucleofected according to manufacturer instructions using the Amaxa Human Stem Cell Nucleofector Kit 1 (Lonza).

To generate an isogenic APP^null^ line in an APP^dp^-patient background, the iPSC-line APP^dp^1.2 was nucleofected with 6 μg CMV::Cas9-2A-eGFP vector and 3 μg U6::gRNA vector. To target the CRISPR/Cas9 we used the gRNA target sequence: 5′-GGAGATCTCTGAAGTGAAGATGG-3′ (see [Table S6](#mmc1){ref-type="supplementary-material"} for all oligos used). Nucleofected iPSCs were replated into a 6 well of MEF feeder cells in the presence of Ri and allowed to recover for 72 hours, 1 × 10^4^ GFP^+^ iPSCs were FACS sorted (FACS Aria IIu, BD Biosciences) and (sparsely) plated on 10 cm MEF-feeder plates in the presence of Ri. After 7 days, individual colonies were manually picked and cultured in individual wells of a 96-well plate. Cells were split and DNA was isolated from individuals wells (quickextract kit, Epicenter), PCR amplified using the primers (APPex16-F: CCC GTA AGC CAA GCC AAC AT, APPex16-R: CAT GCA CGA ACT TTG CTG CC**)** and sequenced using the primer AGGCAGCAGAAGCCTT and aligned against the APP wild-type sequence. Amplified PCR-fragments from non-wild-type colonies were selected, cloned using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen) and sequenced to analyze the (edited) genomic DNA sequence on both alleles. One confirmed APP^null^ line was expanded and differentiated to neural progenitor cells and characterized as detailed in [Figure S3](#mmc1){ref-type="supplementary-material"}. To generate isogenic APPΔcholesterol lines in a CV background, the CV iPSC-line was nucleofected with 3.4 μg of a CMV::Cas9-2A-eGFP vector, 1.6 μg of a TOPO blunt II::gRNA vector, and 50nmol (4ng) repair single-stranded oligonucleotide. To target the CRISPR/Cas9 we used the gRNA target sequence: 5′-GTGTTCTTTGCAGAAGATGTGGG-3′. Repair oligo's to generate E693A and F691+E693A respectively were 5′-Tattgcatttagaaattaaaattctttttcttaatttgttttcaaggtgttctttgcagccgatgtgggttcaaacaaaggtgcaatcattggactcatggtgggcggtgttgtcatagc-3′ and E693A+F691A Repair Oligo Sequence: 5′-ttatattgcatttagaaattaaaattctttttcttaatttgttttcaaggtgttcgctgcagccgatgtgggttcaaacaaaggtgcaatcattggactcatggtgggcggtgttgtcat-3′ respectively.

Nucleofected iPSCs were re-plated into a 6 well of MEF feeder cells in the presence of Ri and and 1 μM SCR7 (Excess Bioscience, M60082-2) and/or 5 μM L-755,507 (Sigma, SML1362).

Cells were then allowed to recover for 48 hours after which, live, GFP+ iPSCs were FACS sorted (FACS Aria IIu, BD Biosciences) and plated at 10,000 cells per 10 cm MEF-feeder plates in the presence of Ri. After 7-14 days, individual colonies were manually picked and cultured in individual wells of 96-well plates. 96 well plates were split and DNA was isolated from each well of one of the plates (quickextract kit, Epicenter). The region of interest was PCR amplified using Forward Primer: 5′-CTTCCTCGAACTGGGGAAGC-3′ and Reverse Primer: 5′-TCACGGTAAGTTGCAATGAATGA-3. Coincidentally, mutation of the wild-type sequence to the sequence corresponding to the E693A mutation generates a novel BbvI restriction motif, whereas introduction of the F691A mutation creates a Pstl restriction enzyme motif. Therefore, initial screening was performed by performing a restriction digest on the PCR-amplified fragment by incubating the PCR amplicon with BbvI (for E693A) or PstI (F691A+E693A). These fragments were run on a DNA-gel and samples in which full restriction had occurred (homozygous for the desired mutation) were confirmed by sequencing of the amplicon using the primer: 5′-CCAACCAGTTGGGCAGAGAA-3′ Once confirmed, two individual IPSC lines containing the homozygous E693A mutation (3D9, 2B2), one line containing the homozygous F691A+E693A mutation (D12) and two unedited controls lines (B10, B11) that underwent the same clonal expansion process were expanded and differentiated to neural progenitor cells.

#### Additional Cell Line Information {#sec4.3.2.3}

The Craig Venter Cell line (CV) as well as all gene edited isogenic lines generated from this line are male. The CV line was previously reported and characterized in [@bib22]. Cell lines generated in this background include the isogenic knockout lines IB6 (APP knockout) and 151 (wt), and the Δcholesterol mutant lines 3D9 and 2B2 (APP E693A), D12 (F691A+E693A), and B10 and B11 (WT controls). All APP^dp^1 (patient 1) derived lines are male, all APP^dp^2 (patient 2) derived lines are female ([@bib29]).

The lines NDC1, NDC2, NDC3, NDC4, NDC5, SAD2, SAD3, SAD6, and SAD7 are male. The lines SAD1, SAD4, and SAD5 are female. The NDC and SAD lines were previously reported and characterized in [@bib29] and [@bib71]. Analyses of the influence of sex was not evaluated in this study. Rather the effect of drug-treatment on individual cell-lines before and after treatment was compared or between isogenic gene-edited lines.

#### Copy number determination {#sec4.3.2.4}

200 ng of DNA was hybridized to Illumina HumanCore arrays (Illumina), and stained per Illumina's standard protocol. Copy Number Variation (CNV) calling was carried out in Nexus CN (version 7.5) and manually inspected, visualizing the B-allele frequencies (proportion of A and B alleles at each genotype) and log R ratios (ratio of observed to expected intensities) for each sample, as described in [@bib13].

#### Generation of neural progenitor cells {#sec4.3.2.5}

NPC's were generated from iPSCs as described previously ([@bib73]). In short, 2 × 10^5^ FACS-purified iPSC TRA1-81^+^ cells were seeded onto two 10 cm plates that were seeded the previous day with 5 × 10^5^ PA6 cells and were cultured in PA6 differentiation media (450ml Glasgow DMEM, 50ml KO Serum Replacer, 5ml sodium pyruvate, 5ml Nonessential Amino Acids) + 10um SB431542+ 0.5ug/ml Noggin. After 6 days in culture, media was changed to PA6 differentiation media without SB431542 and Noggin. At day 11, cells were dissociated with Accutase and ∼5 × 10^5^ CD184^+^CD24^+^CD44^−^CD271^−^ NPCs were FACS-purified and plated onto poly-L-ornithine/laminin-coated plates and cultured with NPCbase + 20ng/ml bFGF (Millipore). Of note, while iPSC are grown in lipid containing media, the derived NPC after sorting (and for neuronal differentiation) are always grown in medium that does not contain an exogenous source of lipids.

#### Cell culture, generation of neurons and astrocytes {#sec4.3.2.6}

iPSCs were cultured on a MEF feeder layer in HUES medium (KO DMEM, knockout serum, plasmanate, pen-strep, non-essential amino acids, glutamax and β-mercaptoethanol) + 20ng/ml bFGF (Millipore) as described previously ([@bib29]) on a MEF feeder layer and passaged with Accutase (Innovative Cell Technologies). NPCs were cultured on poly-L-ornithine (0.02 mg/ml) and laminin (5 ug/ml) (Sigma)-coated plates in DMEM:F12 + Glutamax, 0.5x N2, 0.5x B27, Pen/Strep (all Life Technologies), and 20 ng/ml FGF, and passaged with Accutase. For neuronal differentiation, NPCs were expanded to confluence, after which FGF was withdrawn from the culture medium and the medium was changed twice weekly. For all experiments, unless stated otherwise, neurons after 3 weeks of differentiation were replated into 96 wells (2 × 10^5^ living cells/well) for 2 weeks in 200 ul NPC base + BDNF/GDNF/cAMP. After 2 weeks media was removed and fresh media (200 ul NPC base + BDNF/GDNF/cAMP) containing the tested compounds was added. At indicated time points, the conditioned culture media was harvested from cells and cells were lysed in 70 μL MSD lysis buffer (MSD) with protease (Calbiochem) and phosphatase inhibitors (Halt). For [Figures 4](#fig4){ref-type="fig"}E and 4F (cholesterol mutants) 3-week differentiated neurons were plated for 2 weeks and treated with DMSO and Atorvastatin respectively for 2 days. On day 3 a full media change was performed (containing DMSO or Atorvastatin) and 24 hours later the media was collected for Aβ measurements. For experiments in [Figure 5](#fig5){ref-type="fig"}C, MG132 was added fresh to the media every day. For astrocytic differentiation, a confluent 10 cm plate of NPCs was scraped in NPC medium, and transferred to 3 wells of a 6 well plate placed on a 90 RPM orbital shaker in the incubator to promote neurosphere formation. 24 hours later, 5 μM RI was supplemented to the medium for 48 hours. After 48 hours the neurospheres were grown in NPC medium (withouth FGF) that was replaced every 2 to 3 days. One week after scraping, media was changed to Astrocyte Growth Medium (AGM) containing 3% FBS, ascorbic acid, rhEGF, GA-1000, insulin, and L-glutamine (Lonza) and cell were cultured for an additional two weeks. After two weeks, the neurospheres were plated on a poly-L-ornithine/laminin-coated 10 cm plate. After seven days the astrocytes emerging from the neurospheres were passaged with Accutase, cultured in AGM, and maintained with the neurospheres.

#### Neuron FACS sort {#sec4.3.2.7}

For Aβ measurements in purified Δcholesterol mutant neurons ([Figure 4](#fig4){ref-type="fig"}D) and tau measurements in the APPdp and APP^null^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}I), neurons were purified to compare steady state Aβ measurement within different lines. After three weeks of neuronal differentiation in NPCbase media without FGF; CD184^-^, CD44^-^, CD24^+^ (antibodies from BD Bioscience) neurons were purified by FACS (BD Biosciences) and were plated onto poly-L-ornithine/laminin-coated coated plates. Sorted neurons were cultured in NPCbase media + 0.5mM dbCAMP, 20ng/mL BDNF, and 20ng/mL GDNF for 5-7 days before experiments.

Method Details {#sec4.4}
--------------

### Reagents {#sec4.4.1}

Compounds used are T0901317 (Sigma, T2320) GW501516 (Enzo life sciences, 89150-762), Rosiglitazone (Sigma, R2408), Atorvastatin calcium salt (Sigma, PZ001), Simvastatin (Sigma, S6196), Rosuvastatin (Sigma, SML1264), Fluvastatin (Sigma, SML0038), Mevastatin (Tocris, 1526) Lovastatin (Sigma, PHR1285), Mevalonolactone (Mevalonic Acid) (Sigma, M4777), (R)-Mevalonic acid 5-pyrophosphoate tetralithium salt (Sigma, 77631), Mevalonic acid 5-phosphate thrilithium salt hydrate (Sigma, 79849), Methyl-β-cyclodextrin (Sigma, C4555), YM-53601 (Cayman Chemicals, 18113), AY 9944 dihydrochloride (Tocris), FTI-227 trifluoroacetate salt (Sigma, F9803), GGTI-298 trifluoracetate salt hydrate (Sigma, G5169), Fatostatin hydrobromide (Sigma, F8932), 24(S)-hydroxycholesterol (Cayman Chemicals, 10009931), K-604 (Sigma-Aldrich, SML1837), chloroquine diphosphate salt (Sigma, C6628), MG-132 (InSolution, Calbiochem, 37391), Cholestane (Sigma-Aldrich C8003) *N*-Methyl-*N*-(trimethylsilyl)trifluoroacetamide (MSTFA, ThermoFisher TS48910), 1 μL of dry pyridine (Sigma-Aldrich, 270970) and sodium hydroxide solution 10M (BioUltra, Sigma Aldrich, 72068).

The compound collection for the screen consisted of 1684 FDA and EMA approved drugs, as well as drugs that had been tested in clinical trials. This collection was assembled from multiple commercially available libraries, including the Prestwick Chemical Library (Prestwick Chemical), Microsource US and International Drug Collections (Microsource Discovery Systems, Inc.), and NIH clinical collection libraries (<http://www.nihclinicalcollection.com>). An overview of all compounds in the screen can be found in [Table S1](#mmc2){ref-type="supplementary-material"}.

### Phenotypic high-throughput screen {#sec4.4.2}

After thawing, APP^dp^1-6 NPC's (passage 13) were expanded to confluence on 10cm dishes and differentiated at passage 16 (p16) by withdrawal of bFGF. After 3 weeks, differentiated NPC's were washed with PBS and dissociated using Accutase:Accumax (Innovative Cell Technologies) (1:1). Cells were resuspended in sort buffer (NPCbase Media+ 1% FBS (Mediatech 35-011-CV)+2.5mM EDTA) and filtered through a sterile cell strainer (100um, Fisher scientific, Cat no. 22363549) to remove clumps. Cells were spun down (5 min at 1000RPM) and resuspended in NPCbase + 20 ng/μl BDNF, 20 ng/μl GDNF (Peprotech) and 0.5 mM dbcAMP (Sigma).

Cells were plated in 384 well poly-L-ornithine/laminin-coated plates at 5 × 10^4^ live cells/well in 50 μL and were allowed to further mature for 2 weeks. After 1 week, 25 μL media was aspirated and replaced with fresh media (NPC base + BDNF/GDNF/cAMP). 1 week later (in total 2 weeks on the 384 well plate) 15 μL of media was aspirated (leaving 35 μL in the well) and 35 μL media + 2x compound (NPC base + 2x BDNF/GDNF/cAMP and 10 μM of compound) was added to generate a final concentration of 5 μM compound/well or vehicle (DMSO, 16 wells per 384 well plate) in duplicate. After five days of treatment, media was aspirated and cells were lysed in 70 μL Mesoscale discovery lysis buffer (MSD R60TX-3) with protease (Calbiochem) and phosphatase inhibitors (Halt) and lysates were stored at −80 awaiting analysis. From the lysates viability was measured using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) according to manufacturer instructions with a modified ratio of lysate to CeLLTiterGlo reagent (1:1) and pThr231/tTau levels were determined using Phospho(Thr231)/Total Tau kit (K15121D, Meso Scale Discovery). For each 384 well plate, Z-scores were determined for each data point, as the number of standard deviations from the mean of the control, vehicle-treated (DMSO) wells. Compounds that decreased pThr231Tau/tTau by Z \< −2 in one of the duplicates were selected for confirmational screening (repeat of the methods described for the primary screen). Compounds that decreased pThr231Tau/tTau in an additional replicate (Z \< −2) in the secondary screen were defined as hits.

### Aβ, pThr231Tau/total Tau, pSer9GSK3b/total Gsk3b, Phospho-4E-BP1(Thr37/46)/total 4E-BP1 ELISA Measurements {#sec4.4.3}

For Aβ measurements, 25 μL of the culture media was run on a V-PLEX Aβ Peptide Panel 1 (6E10) (K150SKE) kit, for pThr231Tau/tTau lysate was run on a Phospho (Thr231)/Total Tau Kit (K15121D), for pSer9GSK3β/total Gsk3β lysate was run on pSer9GSK3β /total Gsk3β Kit (K15109D). For Phospho-4E-BP1(Thr37/46)/total 4E-BP1 lysates were run separately on a Phospho-4E-BP1(Thr37/46) kit (K150KHD) and a total 4E-BP1 kit (K151OLD) and ratio was determined by combining these two measures from the same lysates. All kits from Mesoscale discovery. Measurements were performed on Mesoscale discovery sector imager 600. For [Figure 4](#fig4){ref-type="fig"}D (cholesterol mutants) purified neurons were replated after FACS and media was collected after 5 days.

### Cell viability {#sec4.4.4}

From the lysates viability was measured using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) according to manufacturer instructions with a modified ratio of lysate to CeLLTiterGlo reagent (1:1). CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) and Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific) were performed in 96-well plates in accordance with manufacturer instructions.

### Mass spectrometry sample preparation and LC-MS-MS {#sec4.4.5}

The frozen cell pellet was resuspended in an equal volume of water and then vortexed to thaw the sample. We added 100 ul of cell suspension to 500μl of 6 Molar Guanidine solution followed by vortexing. The sample was then boiled for 5 minutes followed by 5 minutes cooling at room temperature, this step was repeated 3 times. The proteins were precipitated with addition of methanol followed by vortex and centrifugation at 14000 rpm for 10 minutes. The soluble fraction was removed. The pellet was resuspended in 600ul of 8 M Urea made in 100mM Tris pH 8.0 and by vortexing for 5-10 minutes. TCEP was added to final concentration of 10 mM. The sample was then frozen overnight at −20C. Next day the solution was thawed and vortexed for another 5 minutes until the solution became clear. Chloro-acetamide solution was added to final concentration of 40 mM and vortexed for 5 minutes. Equal volume of 50mM Tris pH 8.0 was added to the sample to reduce the urea concentration to 4 M. Lys C was added in 1:500 ratio of LysC to protein content and incubated at 37C in a rotating incubator for 4-6 hours. Equal volume of 50mM Tris pH 8.0 was added to the sample to reduce the urea concentration to 2 M. Trypsin was added in 1:50 ratio of trypsin to protein content. Next day the solution was acidified using TFA (0.5% TFA final concentration) and vortexed for 5 minutes. The sample was centrifuged at 15, 700 g for 5 min to obtain aqueous and organic phases. The lower aqueous phase was collected and desalted using 100 mg C18-StageTips as described by the manufacturer protocol. The peptide concentration of sample was measured using BCA after resuspension in sample loading buffer and the total of 2 ug is injected for each label free quantification run. Trypsin-digested peptides were analyzed by ultra high pressure liquid chromatography (UPLC) coupled with tandem mass spectroscopy (LC-MS/MS) using nano-spray ionization. The nanospray ionization experiments were performed using a Orbitrap fusion Lumos hybrid mass spectrometer (Thermo) interfaced with nano-scale reversed-phase UPLC (Thermo Dionex UltiMate 3000 RSLC nano System) using a 25 cm, 75-micron ID glass capillary packed with 1.7-μm C18 (130) BEH™ beads (Waters corporation). Peptides were eluted from the C18 column into the mass spectrometer using a linear gradient (5%--80%) of ACN (Acetonitrile) at a flow rate of 375 μl/min for 1h. The buffers used to create the ACN gradient were: Buffer A (98% H~2~O, 2% ACN, 0.1% formic acid) and Buffer B (100% ACN, 0.1% formic acid). Mass spectrometer parameters are as follows; an MS1 survey scan using the orbitrap detector (mass range (m/z): 400-1500 (using quadrupole isolation), 120000 resolution setting, spray voltage of 2200 V, Ion transfer tube temperature of 275 C, AGC target of 400000, and maximum injection time of 50 ms) was followed by data dependent scans (top speed for most intense ions, with charge state set to only include +2-5 ions, and 5 s exclusion time, while selecting ions with minimal intensities of 50000 at in which the collision event was carried out in the high energy collision cell (HCD Collision Energy of 30%), and the fragment masses where analyzed in the ion trap mass analyzer (With ion trap scan rate of turbo, first mass m/z was 100, AGC Target 5000 and maximum injection time of 35ms). Protein identification and label free quantification was carried out using Peaks Studio 8.5 (Bioinformatics solutions Inc.)

### Lipid measurements {#sec4.4.6}

For the analysis of cholesterol and its precursors by means of gas chromatography mass spectrometry (GC-MS), treated neurons were pelleted by centrifugation and resuspended in 50 μL water. 600 μL MTBE and 160 μL methanol was added and samples were vortexed and shaken at room temperature for 30 minutes. For phase separation 200 μL water was added. Samples were spun at 16.100 g for 5 minutes and the organic (soluble) extract (350 μL) was separated from the pelleted protein. Extraction was repeated by the addition of 100 μL methanol, 100 μL water and 300 μL MTBE. After centrifugation the organic extracts were combined (650 μL) and split into two fresh glass vials (one for the total cholesterol fraction (200μL) and one for free cholesterol fraction (450μL)). Samples were dried under a gentle stream of nitrogen. For free cholesterol analysis, 10 μL of an internal standard solution (IS) containing 10 μg/mL cholestane in MTBE, 50 μL of *N*-Methyl-*N*-(trimethylsilyl)trifluoroacetamide (MSTFA), 1 μL of dry pyridine and 39 μL of MTBE were added to the dried extract. The samples were kept at room temperature for 30 minutes in order to complete derivatization before injection. For total cholesterol analysis, 10 μL IS solution, 400 μL LC-MS grade water and 100 μL 10M NaOH were added and samples were heated to 60°C for one hour. After samples had cooled to room temperature sterols were extracted twice using 750 μL MTBE. The combined organic extracts were dried under a gentle stream of nitrogen and dissolved in 50 μL of MSTFA, 1 μL of dry pyridine and 49 μL of MTBE. Samples were kept at room temperature for 30 minutes before injection. GC-MS analysis was carried out on a ScionTQ GC-MS system (Bruker Daltonics). Helium (99.9990%) was used as carrier gas on an Agilent VF-5ms column (5% phenyl-methyl; 25 m × 0.25 mm internal diameter; 0.25 μm film thickness). The injector was kept at 280°C and 1 μL was injected split-less. The oven program started at 50°C, held for 1 minute, followed by a ramp of 50°C/min to 260°C, continued to ramp with 4°C/min to 310°C, held for 0.3 minutes. Sterols were identified based on their relative retention time and comparison of electron ionization mass spectra ([@bib21], [@bib49]). For quantification of free and total cholesterol an external calibration line from 0-500 μg/mL cholesterol was constructed. Total ion current chromatograms were integrated and quantified by the use of the external calibration lines. Pelleted protein was resuspended in 2% SDS and quantified according to the manufacturers instructions using the Pierce BCA Protein Assay Kit (cat. no. 23225).

Quantitative cholesterol ester and phospholipid analysis was carried out using a commercial platform (The Lipidyzer, Sciex, Redwood, CA, USA). In brief, treated neurons were pelleted by centrifugation and resuspended in 100 μL water and 100 μL internal standard mixture in methyl-tert.-butyl ether (MTBE). An additional 500 μL MTBE and 160 μL methanol was added and samples were vortexed and shaken at room temperature for 30 minutes. For phase separation 200 μL LC-MS grade water was added and samples were spun for 3 minutes at 16.100 × g. The upper organic layer was transferred to a glass vial. The extraction was repeated after the addition of 300 μL MTBE, 100 μL methanol and 100 μL water. The combined organic extracts were dried under a gentle stream of nitrogen and 250 μL running buffer was added. The analysis was carried out using the commercial flow-injection based quantitative lipidomics platform (The Lipidyzer). For analysis of relative cholesterol ester levels the cumulative concentrations of all cholesterol esters detected was normalized over the cumulative concentration of all sphingomyelins detected.

### Microscopy {#sec4.4.7}

After differentiation, neurons were directly fixed or replated on 96-well imaging plates at a density of 2 × 10^5^ living cells per well. Cells were imaged either 1 week (APPΔcholesterol mutants, supplemental 4b) or 2 weeks + 5 days drug treatment (APP^dp^1-6 lines, [Figure 1](#fig1){ref-type="fig"}C) after replating. Cells were fixed with 4% PFA + 4% sucrose for 15 minutes at room temperature, washed 3 times with PBS, permeabilized with 0.1% Triton X-100, blocked with 0.5% BSA/PBS for 30 minutes and incubated with primary antibodies in 0.5% BSA/PBS for 1 hour at room temperature. Cells were subsequently washed 3 times with PBS, incubated with secondary antibodies in 0.5% BSA/PBS for 45 minutes and washed 3 more times with PBS (with the first wash containing 1:1000 DAPI). After 3 washes 100 μL PBS was added to each well and samples were imaged. The antibodies used for immunofluorescence experiments were anti-total Tau clone 7 (MAB2239, 1:100, EMD Millipore), anti-pS202/T205 Tau (CP13, 1:50 Peter Davies), anti-pS396/S404 Tau (PFH1, 1:50 Peter Davies), anti-pThr231 conformational (TG3, 1:50 Peter Davies), anti-MAP2 ab5392 (1:1000, Abcam) and anti-neurofilament 131/132 (SMI31) (1:5000, Covance). Anti-Nestin (BD biosciences, Clone 25/NESTIN (RUO), 611658)

S100b (Proteintech, 15146-1-AP) Secondary antibodies were Alexa Fluor anti-mouse, anti-rabbit and anti-chick (Invitrogen) and used at 1:200. Images for [Figures 1](#fig1){ref-type="fig"}E, [6](#fig6){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}F, and [S4](#mmc1){ref-type="supplementary-material"}A were acquired on a Leica TCS SPE confocal microscope, images for [Figures S1](#mmc1){ref-type="supplementary-material"}A, S1B, and [S5](#mmc1){ref-type="supplementary-material"}A were acquired on a Nikon A1 confocal microscope.

### RNA expression analysis {#sec4.4.8}

For mRNA expression analysis, RNA was isolated using the RNeasy Mini Kit (QIAGEN) and DNase-treated using TURBO DNase (Ambion) for one hour at 37°C. cDNA was generated from RNA primed with oligo(dT) using the SuperScript First-Strand Synthesis System (Invitrogen). We performed RT-qPCR using FastStart SYBR Green (Roche) using an Applied Biosystems 7300 RT-PCR system. Data was analyzed using the delta-Ct method and target genes were normalized to the geometric mean of a housekeeping gene (RPL27). The following primers were used: *HMGCR-F*: CGT GGA ATG GCA ATT TTA GGT CC, *HMGCR-R*: ATT TCA AGC TGA CGT ACC CCT, *LDLR-F*: GTC TTG GCA CTG GAA CTC GT, *LDLR-R*: CTG GAA ATT GCG CTG GAC, PSMB5 FW: GCTACCGGTGAACCAGCG, PSMB5 RV: CAACTATGACTCCATGGCGGA, PSMC2 FW: TGAGAGTGGGCGTGGATAGA, PSMC2 RV: GTACCGGGTGGACCAAAGAG, *RPL27-F*: AAA CCG CAG TTT CTG GAA GA, *RPL27-R*: TGG ATA TCC CCT TGG ACA AA.

### Quantitative western blot {#sec4.4.9}

NPCs were differentiated in 6 wells for 3 weeks and treated for 5 days with compound after which cells were lysed in RIPA Lysis Buffer (Millipore) with protease (Calbiochem) and phosphatase inhibitors (Halt). Protein concentrations were determined (Pierce BCA Protein Assay Kit, Thermo Fisher) and normalized. 4x LDS Sample buffer (novex) + β-mercaptoethanol was added to the lysate to generate a final concentration of 1x sample buffer + 5% β-mercaptoethanol. Samples were boiled (100°C) for 5 minutes. Equal amounts of lysates were run on NuPAGE 4%--12% Bis-Tris gels (Invitrogen), transferred to nitrocellulose or PVDF membranes, and blocked for one hour at room temperature using Odyssey Blocking Buffer (LI-COR). Blots were probed overnight at 4°C using the corresponding primary antibodies followed by IRDye secondary antibodies (LI-COR) at 1:5,000 and images were acquired by LICOR Odyssey imager. Bands were quantified using ImageJ software. Western blot images within one panel showing a composition of bands of interest for a particular immunogen are always from the same image (identical blot and exposure), but cropped and grouped together for clarity. Stiches are indicated by vertical lines. Antibodies used were: anti-Actin (1:50,000; EMD Millipore), anti-APLP2 (1:1,000; Calbiochem), anti-APP A4 clone 22C11 (1:1,000; EMD Millipore), anti-APP C-Terminal (1:500; EMD Millipore), anti-pS202/T205 Tau (CP13, 1:500 Peter Davies), anti-pS396/S404 Tau (PHF1, 1:500 Peter Davies), anti-total Tau T6402 (1:1000, Sigma), anti-total Tau clone 7 (MAB2239, 1:1000, EMD Millipore), anti-histone 3 clone 06-755 (1:1000, Upstate), anti-LC3b (NB600-1384, 1:1000, Novus biologicals), anti-ubiquitin (MAB1510, 1:250, EMD Millipore), Phospho-4E-BP1 (Thr37/46) (Antibody \#9459, 1:1000 Cell Signaling), p70 S6 Kinase Antibody (Antibody \#9202, 1:1000 Cell Signaling), 4E-BP1 Antibody (Antibody \#9452, 1:1000 Cell Signaling) and Phospho-p70 S6 Kinase (Thr389) (108D2, Antibody \#9452, 1:1000 Cell Signaling). Vamp2 (aka synaptobrevin 2) (synaptic systems 104 211) Syntaxin 1 (polyclonal \#I379, gift from the Thomas Sudhof lab to the CNCR FGA department), Synaptotagmin (polyclonal \#W855, gift from the Thomas Sudhof lab to the CNCR FGA department), Munc18/STXBP1 (BD biosciences, Clone 31/Munc-18 (RUO), 610337)

### Proteasomal levels and activity {#sec4.4.10}

After treatment of neurons with the indicated drugs for three days, neurons were incubated with Proteasome activity probe 1 ([@bib5], [@bib14]) for two hours (250 nM in media). After labeling, cells were harvested and resuspended in HR buffer (50 mM Tris, 5 mM MgCl2, 250 mM sucrose, 1 mM DTT and 2 mM ATP, pH = 7.4). Cell lysis was achieved by sonication (Bioruptor Pico, Diagenode, high intensity for 5 minutes with an ON/OFF cycle of 30 s) at 4°C. After a centrifugation step (21.100 g for 15 minutes) to remove cell debris, protein concentration of the supernatant was determined by a NanoDrop spectrophotometer (Thermo Fisher Scientific) by measuring the absorbance at 280 nm. Equal amounts of protein were denatured by boiling in LDS (lithium dodecyl sulfate) sample buffer (Invitrogen Life Technologies, Carlsbad, CA, USA) containing 2.5% β-mercaptoethanol. Polypeptides were resolved by 12% SDS-PAGE using the NuPAGE system and MOPS running buffer (Invitrogen Life Technologies, Carlsbad, CA, USA). Wet gel slabs were imaged with a resolution of 50 μm, using the Typhoon FLA9800 imaging system (GE), with appropriate filter settings (λ(ex/em) = 480/530 nm). For Western Blot analysis, proteins were transferred onto PVDF membrane using the Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked with 5% BSA solution and subsequently incubated with primary antibody overnight at 4°C. After washing with PBS-Tween 20 (0.2%) membranes were incubated with secondary antibody and signals visualized by using an Amersham Imager 600 RGB (GE) imager or Odyssey Fc (Li-Cor). Western blot images within one panel showing a composition of bands of interest for a particular immunogen are always from the same image (identical blot and exposure), but cropped and grouped together for clarity. Stiches are indicated by vertical lines. Immunoblotting with an antibody against GADPH or actin was used to verify equal protein loading. Antibodies used were: anti-Actin (1:50,000; EMD Millipore), anti-PSMD7 (1:1000 PSMC2 (D5T1T) Rabbit mAb \#14395), anti-PSMB5 (1:1,000; Enzo Lifesciences, AB_105409012), anti-GAPDH (1:1000; Life Technologies, AB_2536381). Secondary antibodies used (1:5000) were HRP-conjugated polyclonal swine anti-rabbit (DAKO Cat\# P0217) and HRP-conjugated polyclonal rabbit anti-mouse (DAKO Cat\# P0161).

### Vectors and viral transduction {#sec4.4.11}

pCMV10-CYP46A1-flag vector was a kind gift from Dr. Rodrigues Elsa, University of Lisbon. CYP46A1-Flag was amplified by primers gtacaaaaaagcaggcttaaatggactacaaagaccatgacgg and GTACAAGAAAGCTGGGTAGCggatccTCAGCAGGGGGGTGGT and subcloned into the gateway entry vector pENTRrz1 and subsequently recombined into the destination vector pDESTlentiFGA1.0. Viral particles containing the CYP46A1 plasmid, or an GFP-only plasmid (pSyn(pr)EGFPLL3.7) were produced as described previously ([@bib52]). In short HEK293T cells were transfected with viral packing plasmids ENV plasmid p.MDG2:PACK plasmid pCMVΔR8.2 together with the transgene vector carrying GFP or CYP46A1. After 24 hours the medium is replaced, and after 48 hours the medium is harvested and concentrated using amicon filters with 100kDA cutoff (UFC910024, Millipore). The concentrated virus is then filtered through a 0.2 micron filter, aliquoted and frozen at −80 degrees. For use, virus is thawed directly prior to vial transduction. For experiments, three week differentiated NPC's (APPdp1-6) were replated on 96-well plates (2 × 10^5^ living cells/well) and left to mature for another two weeks, after which they were infected with virus for 24 hours. After 24 hours, and again after 6 days media was replaced with fresh 200 μl NPC base + BDNF/GDNF/cAMP. 13 days after viral transduction the media was collected for 24-hydroxycholesterol measurements and cells were lysed for pThr231Tau/tTau analysis.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical Analysis {#sec4.5.1}

The correlation coefficient (CC) for [Figure 3](#fig3){ref-type="fig"}E was calculated in excel using the formula$$Correl\left( {X,Y} \right) = \frac{\sum{\left( {x - \overline{x}} \right)\left( {y - \overline{y}} \right)}}{\sqrt{\sum\left( {x - \overline{x}} \right)^{2}\sum\left( {y - \overline{y}} \right)^{2}}}$$All other data was analyzed using GraphPad Prism Software (GraphPad Software). Statistical analysis comparing multiple groups was performed using a one-way Anova with a Tukey's multiple comparison test. Statistical analysis comparing two groups (treated versus untreated groups within the same genotype were calculated using multiple t tests. Data are depicted with bar graphs of the mean ± SEM of all values. Significance was defined as p \< 0.05(^∗∗∗^ p \< 0.001, ^∗∗^ p \< 0.01, ^∗^p \< 0.05). n indicates independent measures from independent wells.
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